Eur J Surg Oncol 2001, 27: 125–134.CrossRefPubMed 5. Sugarbaker PH: Peritonectomy procedures. Ann Surg 1995, 221: 29–42.CrossRefPubMed 6. Sugarbaker PH, Yonemura Y: Clinical pathway for the selleck inhibitor management of resectable gastric cancer SHP099 with peritoneal seeding: best palliation with a ray of hope for cure. Oncology 2000, 58: 96–107.CrossRefPubMed 7. Gilly FN, Carry PY, Sayag AC, Brachet A, Panteix G, Salle B, et al.: Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia

for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 1994, 41: 124–129.PubMed 8. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T: Successful intraperitoneal hyperthermic chemoperfusion Abemaciclib chemical structure for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999, 85: 529–534.CrossRefPubMed 9. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T, Isawa E, et al.: Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 1997, 79: 884–891.CrossRefPubMed 10. Glehen O, Mohamed F, Gilly FN: Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet

Oncol 2004, 5: 219–228.CrossRefPubMed 11. Lindhofer H, Mocikat R, Steipe B, Thierfelder S: Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995, 155: 219–225.PubMed 12. Kiewe P, Hasmuller S, Kahlert S, Heinrigs M, Rack B, Marme A, et al.: Phase I trial of the trifunctional anti-HER2 × anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 2006, 12: 3085–3091.CrossRefPubMed 13. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, et al.: Simultaneous activation of T cells and accessory cells next by a new class of intact bispecific antibody results in efficient tumor cell

killing. J Immunol 1999, 163: 1246–1252.PubMed 14. Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, et al.: The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000, 83: 261–266.CrossRefPubMed 15. Ruf P, Lindhofer H: Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001, 98: 2526–2534.CrossRefPubMed 16. Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, Baeuerle PA, et al.: Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 2006, 103: 483–488.CrossRefPubMed 17. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, et al.